[HTML][HTML] High-dose atorvastatin causes a rapid sustained increase in human serum PCSK9 and disrupts its correlation with LDL cholesterol
G Welder, I Zineh, MA Pacanowski, JS Troutt… - Journal of lipid …, 2010 - ASBMB
Proprotein convertase subtilisin kexin type 9 (PCSK9) is a key regulator of serum LDL-cholesterol
(LDL-C) levels. PCSK9 is secreted by the liver into the plasma and binds the hepatic …
(LDL-C) levels. PCSK9 is secreted by the liver into the plasma and binds the hepatic …
The functional G143E variant of carboxylesterase 1 is associated with increased clopidogrel active metabolite levels and greater clopidogrel response
…, WD Figg, SD Spencer, MA Pacanowski… - Pharmacogenetics …, 2013 - journals.lww.com
Methods We genotyped a functional variant in CES1, G143E, in participants of the
Pharmacogenomics of Anti-Platelet Intervention (PAPI) study (n= 566) and in 350 patients with …
Pharmacogenomics of Anti-Platelet Intervention (PAPI) study (n= 566) and in 350 patients with …
[HTML][HTML] New evidence about an old drug—risk with codeine after adenotonsillectomy
…, DW Roberson, MA Pacanowski… - … England Journal of …, 2013 - Mass Medical Soc
New Evidence about an Old Drug — Risk with Codeine after Adenotonsillectomy | NEJM Skip
to main content NEJM Group Follow Us Facebook Twitter Instagram YouTube LinkedIn Prepare …
to main content NEJM Group Follow Us Facebook Twitter Instagram YouTube LinkedIn Prepare …
Pharmacogenetic labeling of FDA-approved drugs: a regulatory retrospective
K Drozda, MA Pacanowski, C Grimstein… - JACC: Basic to …, 2018 - jacc.org
The US Food and Drug Administration recently marked 10 years since first updating the
labeling for warfarin (often referred to as the “poster child” of pharmacogenomics) to include …
labeling for warfarin (often referred to as the “poster child” of pharmacogenomics) to include …
A sensitive and rapid ultra HPLC–MS/MS method for the simultaneous detection of clopidogrel and its derivatized active thiol metabolite in human plasma
…, DAH VanDenBerg, MA Pacanowski… - … of Chromatography B, 2012 - Elsevier
A sensitive, selective, and rapid ultra-high performance liquid chromatography–tandem
mass spectrometry (uHPLC–MS/MS) was developed for the simultaneous quantification of …
mass spectrometry (uHPLC–MS/MS) was developed for the simultaneous quantification of …
Identification of Stevens–Johnson syndrome and toxic epidermal necrolysis in electronic health record databases
…, A Wu, LA La Grenade, MA Pacanowski… - … and drug safety, 2015 - Wiley Online Library
Background Stevens–Johnson syndrome (SJS) and toxic epidermal necrolysis (TEN) carry a
high mortality risk. While identifying clinical and genetic risk factors for these conditions has …
high mortality risk. While identifying clinical and genetic risk factors for these conditions has …
Cardiovascular therapies and associated glucose homeostasis: implications across the dysglycemia continuum
RM Cooper-DeHoff, MA Pacanowski… - Journal of the American …, 2009 - jacc.org
Certain cardiovascular drugs have adverse effects on glucose homeostasis, which may
lead to important long-term implications for increased risks of adverse outcomes. Thiazide …
lead to important long-term implications for increased risks of adverse outcomes. Thiazide …
Effectiveness of clopidogrel dose escalation to normalize active metabolite exposure and antiplatelet effects in CYP2C19 poor metabolizers
…, AR Shuldiner, MA Pacanowski - The Journal of …, 2014 - Wiley Online Library
Carriers of two copies of the loss‐of‐function CYP2C19*2 variant convert less clopidogrel
into its active metabolite, resulting in diminished antiplatelet responses and higher …
into its active metabolite, resulting in diminished antiplatelet responses and higher …
Pharmacogenomics in the assessment of therapeutic risks versus benefits: inside the United States Food and Drug Administration
I Zineh, MA Pacanowski - Pharmacotherapy: The Journal of …, 2011 - Wiley Online Library
Pharmacogenomics is the study of how genetic variations influence responses to drugs,
diagnostics, or biologic agents. The field of pharmacogenomics has significant potential to …
diagnostics, or biologic agents. The field of pharmacogenomics has significant potential to …
Allopurinol pharmacogenetics: assessment of potential clinical usefulness
…, SH Chang, H Rogers, MA Pacanowski - …, 2011 - Future Medicine
Use of pharmacogenetics to inform treatment decisions remains a priority for clinicians,
patients and public health agencies. We previously developed a framework for systematically …
patients and public health agencies. We previously developed a framework for systematically …